Putnam Investments’s Immune Design Corp. IMDZ Stock Holding History

Putnam Investments’s Portfolio IMDZ Stock Details IMDZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-218,362	Closed	-$1.2M	–	1348
2016 Q4	$1.2M	Sell	218,362 -35,024	-14%	-$247K	﹤0.01%	966
2016 Q3	$1.92M	Sell	253,386 -29,297	-10%	-$214K	﹤0.01%	856
2016 Q2	$2.31M	Sell	282,683 -973	-0.3%	-$12.1K	0.01%	885
2016 Q1	$3.69M	Buy	283,656 +1,674	+0.6%	+$19.3K	0.01%	766
2015 Q4	$5.66M	Sell	281,982 -1,008	-0.4%	-$17.4K	0.01%	619
2015 Q3	$3.45M	Buy	282,990 +1,459	+0.5%	+$27.3K	0.01%	807
2015 Q2	$5.81M	Buy	+281,531	New	+$6.65M	0.01%	664

Other funds holding IMDZ

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Putnam Investments's IMDZ Position: Q1 2017 in Review

Putnam Investments sold out of Immune Design Corp. (IMDZ) in Q1 2017, closing a stake of 218,362 shares — an estimated $1.2M sold.

Putnam Investments first reported a position in IMDZ in Q2 2015 and held it in 7 quarters. The position peaked at $5.81M in Q2 2015. 58 funds tracked by Wall St. Rank hold IMDZ as of Q1 2017.

Putnam Investments reported no remaining Immune Design Corp. position as of Q1 2017 after selling out during the quarter.
Putnam Investments sold 218,362 Immune Design Corp. shares in Q1 2017, an estimated $1.2M.
Putnam Investments first reported a position in Immune Design Corp. in Q2 2015 and held it in 7 quarters.
Putnam Investments's Immune Design Corp. position peaked at $5.81M in Q2 2015.
58 funds tracked by Wall St. Rank held Immune Design Corp. as of Q1 2017.

Based on Putnam Investments's 13F filing for Q1 2017, filed 15 May 2017.